Cardiff Oncology doses first subject with onvansertib in Phase two ONSEMBLE trial

Codagenix names new chief strategy officer

FDA removes partial clinical hold on Blueprint Medicines' Phase 1/2 BLU-222 trial

Global Bioengineered Protein Drugs Market to Reach USD 521.3bn by 2027, According to Research and Markets

Enrollment Begins in FORESEE Clinical Trial Using Biocept's CNSide to Evaluate Patients with Leptomeningeal Metastases

Aadi Bioscience names new director

ONO Pharma USA's Tirabrutinib (ONO-4059) receives FDA Orphan Drug Designation

Shanghai Henlius Biotech's EMA application for HANSIZHUANG (serplulimab) in combination with chemotherapy receives validation

InvoX Pharma's F-star Announces Licence Agreement with Takeda for Second Novel Next-Generation Immuno-Oncology Bispecific Antibody

Bayer plans new clinical trial for NUBEQA in prostate cancer

Pionyr Immunotherapeutics and Gilead amend 2020 agreements

BioAI Health adds new advisory board member

Debiopharm doses first patient in its GaLuCi first-in-human, phase 1/2 study for its CA IX-targeted radiopharmaceutical program

Shuttle Pharmaceuticals signs research agreement with Georgetown University for SP-2-225 assessment

Transcenta Holding doses first subject in TST003 US phase one study